Performance of plasma biomarkers for diagnosis and prediction of dementia in a Brazilian cohort

Luis E. Santos, Paulo Mattos, Thais L. Pinheiro, Ananssa Silva, Claudia Drummond, Felipe Kenji Sudo, Fernanda Barros-Aragão, Bart Vanderborght, Carlos Otávio Brandão, Sergio T. Ferreira, Fernanda Tovar-Moll () and Fernanda G. Felice ()
Additional contact information
Luis E. Santos: D’Or Institute for Research and Education (IDOR)
Paulo Mattos: D’Or Institute for Research and Education (IDOR)
Thais L. Pinheiro: D’Or Institute for Research and Education (IDOR)
Ananssa Silva: D’Or Institute for Research and Education (IDOR)
Claudia Drummond: D’Or Institute for Research and Education (IDOR)
Felipe Kenji Sudo: D’Or Institute for Research and Education (IDOR)
Fernanda Barros-Aragão: D’Or Institute for Research and Education (IDOR)
Bart Vanderborght: D’Or Institute for Research and Education (IDOR)
Carlos Otávio Brandão: Neurolife – Cerebrospinal Fluid Specialized Laboratory
Sergio T. Ferreira: D’Or Institute for Research and Education (IDOR)
Fernanda Tovar-Moll: D’Or Institute for Research and Education (IDOR)
Fernanda G. Felice: D’Or Institute for Research and Education (IDOR)

Nature Communications, 2025, vol. 16, issue 1, 1-11

Abstract: Abstract Despite remarkable progress in the biomarker field in recent years, local validation of plasma biomarkers of Alzheimer’s disease (AD) and dementia is still lacking in Latin America. In this longitudinal cohort study of 145 elderly Brazilians, we assess the diagnostic performance of plasma biomarkers, based on clinical diagnosis and CSF biomarker positivity. Follow-up data of up to 4.7 years were used to determine performance in predicting diagnostic conversions. Participants were clinically categorized as cognitively unimpaired (n = 49), amnestic mild cognitive impairment (n = 29), AD (n = 38), Lewy body dementia (n = 22), or vascular dementia (n = 7). Plasma Tau, Aβ40, Aβ42, NfL, GFAP, pTau231, pTau181 and pTau217 were measured on the SIMOA HD-X platform. Plasma pTau217 showed excellent performance determining CSF biomarker status in the cohort, either alone (ROC AUC = 0.94, 95% CI: [0.88–1.00]) or as a ratio to Aβ42 (ROC AUC = 0.98, 95% CI: [0.94–1.00]). This study comprises an initial step towards local validation and adoption of dementia biomarkers in Brazil.

Date: 2025
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-025-56756-3 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-56756-3

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-025-56756-3

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().